VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Vanda Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.09+0.06 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $246.33M
- P/E (TTM)
- –
- Dividend yield
- –
Vanda Pharmaceuticals Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fanapt | $35.99M | $29.56M | $33.22M | $31.25M | $29.29M | $23.55M | $26.65M | $23.92M | $23.15M | $20.58M | $22.60M | $21.32M | 71.2% | +22.9% |
| PONVORY net product sales | $7.94M | $6.21M | $7.61M | $7.04M | $7.10M | $5.62M | $6.49M | $5.86M | $8.62M | $6.83M | $1.60M | $0 | 15.7% | +11.7% |
| HETLIOZ net product sales | $5.58M | $15.95M | $16.39M | $17.98M | $16.19M | $20.87M | $20.04M | $17.87M | $18.71M | $20.05M | $21.07M | $17.50M | 11.0% | -65.6% |
| NEREUSTM | $1.03M | – | – | – | $0 | – | – | – | – | – | – | – | 2.0% | – |
By region
From the segment and revenue-disaggregation notes of Vanda Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.